Dolutegravir resistance mutations: lessons from monotherapy studies.

Abstract excerpt

PURPOSE OF REVIEW: Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (InSTI) with an outstanding antiviral potency, good tolerability, good pharmacokinetic profile with a lack of major drug-drug interactions, and a barrier to resistance higher than the other compounds of the class (raltegravir and elvitegravir) and allegedly as high as that of boosted protease inhibitors. For these...

Topics

Join the communities discussing this publication.

• Drug Resistance, Viral
• Drug Therapy
• Heterocyclic Compounds, 3-Ring
• HIV
• HIV Integrase Inhibitors